Damora Therapeutics, Inc.
DMRA
$31.04
$0.311.01%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.45M | 7.03M | 4.07M | 1.74M | 1.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.99M | 30.81M | 27.39M | 3.16M | 3.42M |
| Operating Income | -34.99M | -30.81M | -27.39M | -3.16M | -3.42M |
| Income Before Tax | -30.92M | -27.74M | -200.69M | -3.13M | -3.43M |
| Income Tax Expenses | 255.00K | 42.00K | 44.00K | -- | 4.00K |
| Earnings from Continuing Operations | -31.17M | -27.78M | -200.74M | -3.13M | -3.44M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -31.17M | -27.78M | -200.74M | -3.13M | -3.44M |
| EBIT | -34.99M | -30.81M | -27.39M | -3.16M | -3.42M |
| EBITDA | -34.99M | -30.81M | -27.38M | -3.15M | -3.42M |
| EPS Basic | -0.39 | -0.39 | -135.60 | -2.36 | -2.60 |
| Normalized Basic EPS | -0.32 | -0.51 | -11.14 | -1.48 | -1.62 |
| EPS Diluted | -0.39 | -0.39 | -135.60 | -2.36 | -2.60 |
| Normalized Diluted EPS | -0.32 | -0.51 | -11.14 | -1.48 | -1.62 |
| Average Basic Shares Outstanding | 61.12M | 33.78M | 1.48M | 1.33M | 1.32M |
| Average Diluted Shares Outstanding | 61.12M | 33.78M | 1.48M | 1.33M | 1.32M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |